DVS Sciences
Citing Rise in Publications, Piper Jaffray Projects Solid Growth for Fluidigm CyTOF in 2015
According to the Piper Jaffray analysis, of the 54 total papers published using CyTOF technology, 25 of them, or 46 percent, were published in 2014.
Fluidigm Q3 Revenues Grow 62 Percent
NEW YORK (GenomeWeb) — Fluidigm said after the close of the market on Thursday that its third quarter revenues increased 62 percent year over year, or 35 percent organically.
Fluidigm Q1 Revenues Rise 77 Percent on Instrument Sales
NEW YORK (GenomeWeb News) – Fluidigm reported after the close of the market Monday that its first quarter revenues increased 77 percent year over year, driven by strong instrument sales as well as contributions from a recent acquisition.
Stanford, Zurich Teams Develop Mass Spec-based Proteomics Technologies for Targeted Tissue Imaging
Premium
Two research teams have separately developed new imaging mass spec technologies for targeted protein measurements in tissue.
Fluidigm said this week that it has agreed to acquire mass cytometry firm DVS Sciences for roughly $207.5 million in company common stock and cash.
May 10, 2013
Apr 26, 2013
Jun 29, 2012
Dec 9, 2011
Jul 15, 2011
Jul 14, 2011
DVS Sciences Raises $14.6M
Apr 26, 2010